Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
14.77
-0.15 (-1.01%)
At close: Nov 14, 2025, 4:00 PM EST
14.48
-0.29 (-1.96%)
After-hours: Nov 14, 2025, 5:29 PM EST
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.
Revenue (ttm)
$17.20M
Revenue Growth
+191.39%
P/S Ratio
108.47
Revenue / Employee
$212,321
Employees
81
Market Cap
1.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MESO News
- 11 days ago - Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation - GlobeNewsWire
- 27 days ago - Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch - GlobeNewsWire
- 5 weeks ago - Ryoncil® Revenues Increase 66% in Second Quarter Post Launch - GlobeNewsWire
- 5 weeks ago - Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 6 weeks ago - Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access - GlobeNewsWire
- 7 weeks ago - Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs - GlobeNewsWire
- 2 months ago - Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences - GlobeNewsWire
- 2 months ago - Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - GlobeNewsWire